Patent application number | Description | Published |
20080206140 | Cspcna Isoform Antibodies and Uses Thereof - Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed. | 08-28-2008 |
20080220540 | Method for purifying cancer-specific proliferating cell nuclear antigen - The method for developing an antibody that exclusively binds to csPCNA. | 09-11-2008 |
20090061432 | CSPCNA ISOFORM MODIFICATIONS AND USES THEREOF - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 03-05-2009 |
20090232882 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 09-17-2009 |
20100240874 | METHOD FOR PURIFYING CANCER-SPECIFIC PROLIFERATING CELL NUCLEAR ANTIGEN - An isolated antibody that binds a cancer specific Proliferating Cell Nuclear Antigen (csPCNA) that binds to the amino acid sequence LeuLysGlnLeuAspAlaGlnGlnThrGlnLeuArgIle AspSerPhePheArgLeuAlaGlnGlnGluLysGluAspAlaLysArg (SEQ ID No. 1). An immunoassay that utilizes an isolated antibody that binds a form of csPCNA that binds to the SEQ ID No. 1 to identify the presence of csPCNA in a sample. | 09-23-2010 |
20110076342 | CANCER PEPTIDE THERAPEUTICS - Cell-permeable caPCNA-derived peptides and their variants serve as therapeutic compositions to reduce the proliferation of cancerous cells and also augment cytotoxic effects of chemotherapeutics. | 03-31-2011 |
20110195510 | csPCNA Isoform Modifications And Uses Thereof - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 08-11-2011 |
20120195978 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 08-02-2012 |
20120258482 | PCNA METHYLTRANSFERASE - Proliferating cell nuclear antigen (PCNA)-dependent glutamate methyltransferases are disclosed that can methylesterify one or more glutamic acid or aspartic acid residues of PCNA. | 10-11-2012 |
20140212510 | CAPCNA PEPTIDE THERAPEUTICS FOR CANCER - Administration of compositions comprising cell-permeable caPCNA-derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins. | 07-31-2014 |